SANBIO COMPANY LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 429 JPY | -0.23% |
|
+3.37% | -38.89% |
| Mar. 19 | SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March | MT |
| Mar. 19 | Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform | MT |
Valuation
| Fiscal Period: January | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 118,587 | 84,773 | 56,092 | 47,323 | 37,882 | 29,511 | - | - |
| Enterprise Value (EV) 1 | 108,941 | 76,292 | 54,059 | 41,524 | 34,093 | 29,737 | 32,545 | 35,354 |
| P/E ratio | -22.7 x | -25 x | -12 x | -7.75 x | -14 x | -8.76 x | -8.21 x | -10 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 265 x | - | - | - | - | - | 44.7 x | 10.4 x |
| EV / Revenue | 244 x | - | - | - | - | - | 49.3 x | 12.5 x |
| EV / EBITDA | -20 x | -13.3 x | -8.33 x | -5.27 x | -7.53 x | -9.57 x | -9.38 x | -12.8 x |
| EV / FCF | -18.7 x | -73.7 x | -8.17 x | -5.58 x | - | -6.83 x | -7.02 x | -8.93 x |
| FCF Yield | -5.34% | -1.36% | -12.2% | -17.9% | - | -14.6% | -14.2% | -11.2% |
| Price to Book | 11 x | 10.4 x | 32.8 x | 12 x | 14.9 x | -180 x | -9.75 x | -5.51 x |
| Nbr of stocks (in thousands) | 51,785 | 51,785 | 51,793 | 63,606 | 66,929 | 68,630 | - | - |
| Reference price 2 | 2,290 | 1,637 | 1,083 | 744.0 | 566.0 | 430.0 | 430.0 | 430.0 |
| Announcement Date | 3/16/20 | 3/17/21 | 3/11/22 | 3/16/23 | 3/18/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: January | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 447.2 | - | - | - | - | - | 660 | 2,832 |
| EBITDA 1 | -5,446 | -5,727 | -6,488 | -7,875 | -4,525 | -3,106 | -3,468 | -2,769 |
| EBIT 1 | -5,486 | -5,802 | -6,620 | -7,899 | -4,540 | -4,040 | -4,230 | -3,470 |
| Operating Margin | -1,226.69% | - | - | - | - | - | -640.97% | -122.56% |
| Earnings before Tax (EBT) 1 | -5,157 | -3,211 | -4,560 | -4,697 | -2,542 | -3,532 | -3,621 | -3,076 |
| Net income 1 | -5,158 | -3,386 | -4,677 | -5,559 | -2,644 | -3,295 | -3,528 | -2,895 |
| Net margin | -1,153.27% | - | - | - | - | - | -534.57% | -102.22% |
| EPS 2 | -100.9 | -65.38 | -90.33 | -95.99 | -40.48 | -49.07 | -52.40 | -42.98 |
| Free Cash Flow 1 | -5,813 | -1,036 | -6,613 | -7,444 | - | -4,352 | -4,635 | -3,958 |
| FCF margin | -1,299.78% | - | - | - | - | - | -702.27% | -139.78% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/17/21 | 3/11/22 | 3/16/23 | 3/18/24 | - | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: January | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 19.46 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3,101 | -2,570 | -3,232 | -3,052 | -1,687 | -1,844 | -2,778 | -4,622 | -1,783 | -1,494 | -1,461 | -1,623 | -3,085 | -640.3 | -813.7 | - |
| Operating Margin | -15,936.2% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | -3,109 | -3,205 | -6 | -2,127 | -886 | 869 | - | -774 | 1,211 | - | -866 | - | -1,858 | 116 | - | - |
| Net income | -3,109 | -3,207 | -178.9 | -2,134 | -981 | -315 | - | -2,154 | 396 | - | -626.2 | - | -1,787 | -96 | - | - |
| Net margin | -15,977.31% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | - | -61.94 | - | -41.21 | -18.95 | -5.980 | - | -39.26 | 8.140 | - | -9.680 | - | -27.59 | -1.400 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 9/14/20 | 3/17/21 | 9/14/21 | 12/15/21 | 6/14/22 | 9/14/22 | 9/14/22 | 12/15/22 | 3/16/23 | 6/14/23 | 9/14/23 | 9/14/23 | 12/14/23 | 3/18/24 | 3/18/24 |
1JPY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: January | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 226 | 3,034 | 5,843 |
| Net Cash position 1 | 9,646 | 8,480 | 2,033 | 5,799 | 3,789 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.0728 x | -0.8748 x | -2.11 x |
| Free Cash Flow 1 | -5,813 | -1,036 | -6,613 | -7,444 | - | -4,352 | -4,635 | -3,958 |
| ROE (net income / shareholders' equity) | -52.4% | -35.7% | -95.1% | -195% | -80.5% | -191% | -958% | - |
| ROA (Net income/ Total Assets) | -34.8% | -45.1% | -48.6% | -74.8% | -46.7% | -66.4% | - | - |
| Assets 1 | 14,824 | 7,505 | 9,628 | 7,428 | 5,661 | 4,963 | - | - |
| Book Value Per Share 2 | 209.0 | 157.0 | 33.00 | 62.10 | 38.10 | -2.400 | -44.10 | -78.00 |
| Cash Flow per Share 2 | -100.0 | -63.90 | -87.80 | -95.60 | -40.30 | -44.80 | -39.10 | -21.30 |
| Capex 1 | 95.7 | 96.2 | 47 | 9 | - | 310 | 360 | 410 |
| Capex / Sales | 21.39% | - | - | - | - | - | 54.55% | 14.48% |
| Announcement Date | 3/16/20 | 3/17/21 | 3/11/22 | 3/16/23 | 3/18/24 | - | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
430
JPY
Average target price
800
JPY
Spread / Average Target
+86.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -38.89% | 193M | |
| +9.15% | 105B | |
| -1.08% | 104B | |
| +5.79% | 22.94B | |
| -11.55% | 22.34B | |
| -7.01% | 19.25B | |
| -37.08% | 17.08B | |
| -9.91% | 16.96B | |
| +7.55% | 14.16B | |
| +40.04% | 12.63B |
- Stock Market
- Equities
- 4592 Stock
- Financials SanBio Company Limited